Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels

• US 5,073,555 A
• Filed: 05/25/1990
• Issued: 12/17/1991
• Est. Priority Date: 04/04/1988
• Status: Expired due to Term

• Current Assignee: Arnold Smith
• Original Assignee: George D. Mcadory
• Inventors: Smith, R. Arnold
• Primary Examiner(s): FRIEDMAN, STANLEY
• Application Number:
  US07/528,885
• Time in Patent Office: 571 Days
• Field of Search: 514/474, 514/252
• US Class Current: 514/250
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/475 having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine vincamine A61K31/4375
• CPC Class Codes: A61K 31/48 Ergoline derivatives, e.g. lysergic acid, ergotamine
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof

Abstract

A new composition, useful as a medicament, contains ascorbate, preferably as metallic salt(s), in combination with a dopamine agonist such as bromocriptine, with the ratio by weight of ascorbate to bromocriptine being 400:1 or greater. This combination, believed to act through stimulation of pituitary production of somatotropin, has a significant ability to stimulate enhanced lymphocyte function to result in method to reduce cholesterol levels in humans.

Claims

1. A method for reducing cholesterol levels in human beings requiring such treatment comprising orally administering to said human being a therapeutically effective amount of a dopamine agonist selected from the group consisting of bromocriptine, lergotrile and pergolide, and an ascorbate.

2. The method according to claim 1 wherein said ascorbate is present as a metallic salt and the dopamine agonist is bromocriptine.

3. The method according to claim 2 wherein the metallic salt is sodium ascorbate.

4. The method according to claim 1 wherein the dopamine agonist is lergotrile.

5. The method according to claim 1 wherein the dopamine agonist is pergolide.

6. A method according to claim 1 wherein the dopamine agonist is administered in an amount ranging from 0.4 to 10.0 milligrams daily.

7. The method according to claim 6 wherein the ascorbate is administered in an amount ranging from 0.25 grams to 20 grams daily.

8. The method according to claim 1 additionally comprising coadministering 0.1 to 800 milligrams of a gonadal hormone on a daily basis.

9. The method according to claim 7 additionally comprising coadministering 0.1 to 800 milligrams of gonadal hormone on a daily basis.